We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-3.85%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.91B
AUM Growth
-$201M
Cap. Flow
+$192M
Cap. Flow %
10.02%
Top 10 Hldgs %
65.78%
Holding
51
New
4
Increased
5
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$105M
2
ELVN icon
Enliven Therapeutics
ELVN
+$64M
3
CSPR
Casper Sleep Inc.
CSPR
+$46.8M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$13.7M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$7.36M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$53.2M
2
SENS icon
Senseonics Holdings Inc
SENS
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 84.29%
2 Technology 12.73%
3 Consumer Discretionary 1.4%
4 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
1
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$295M 15.4%
6,138,797
– –
OYST
2
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$207M 10.84%
5,925,287
– –
SPT icon
3
Sprout Social
SPT
$516M
$144M 7.54%
9,046,080
– –
ALLK
4
DELISTED
Allakos
ALLK
$101M 5.27%
2,268,188
– –
NET icon
5
Cloudflare
NET
$99B
$95.3M 4.98%
4,059,376
– –
ARDX icon
6
Ardelyx
ARDX
$1.22B
$91.7M 4.79%
16,135,047
– –
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.73B
$88.7M 4.63%
2,090,678
– –
BDTX icon
8
Black Diamond Therapeutics
BDTX
$96.8M
$86.1M 4.5%
+3,449,845
New +$105M
AUPH icon
9
Aurinia Pharmaceuticals
AUPH
$1.91B
$75.1M 3.92%
5,172,683
– –
RYTM icon
10
Rhythm Pharmaceuticals
RYTM
$6.81B
$74.8M 3.91%
4,912,306
– –
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$69.7M 3.64%
478,546
– –
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$67.9M 3.55%
4,377,518
– –
ELVN icon
13
Enliven Therapeutics
ELVN
$3.92B
$64.4M 3.36%
+1,004,293
New +$64M
MIRM icon
14
Mirum Pharmaceuticals
MIRM
$6.46B
$58.6M 3.06%
4,187,801
– –
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
$46.5M 2.43%
17,082,611
+1,250,000
+8% +$4.15M
GRTX
16
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$41.4M 2.17%
4,362,986
– –
CSPR
17
DELISTED
Casper Sleep Inc.
CSPR
$26.7M 1.4%
+6,226,040
New +$46.8M
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
$23.2M 1.21%
5,736,363
+3,636,363
+173% +$13.7M
PHAS
19
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$22M 1.15%
6,643,704
– –
CBIO
20
Crescent Biopharma
CBIO
$537M
$20.7M 1.08%
90,890
– –
SENS icon
21
Senseonics Holdings Inc
SENS
$263M
$18.8M 0.98%
1,488,084
-56,329
-4% -$1.13M
TRVI icon
22
Trevi Therapeutics
TRVI
$2.59B
$14.6M 0.76%
4,441,360
– –
LITS
23
Lite Strategy Inc
LITS
$32.8M
$13.7M 0.72%
426,654
– –
CSBR icon
24
Champions Oncology
CSBR
$74.5M
$12.7M 0.66%
1,713,720
+151,220
+10% +$1.06M
GNCA
25
DELISTED
Genocea Biosciences, Inc.
GNCA
$12.4M 0.65%
7,225,676
– –
1
2 3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
GD
Grandfield & Dodd New York $1.77B AUM 23.43% 1-Year Est. Return

NEA Management Company's Q1 2020 Portfolio in Review

As of Q1 2020, NEA Management Company held 51 positions worth $1.91B, down 9.5% from $2.11B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

NEA Management Company deployed $192M of net new capital in Q1 2020, opening 4 new positions and adding to 5 existing holdings. Its largest new stake was Black Diamond Therapeutics: 3,449,845 shares worth $86.1M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 86% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Senseonics Holdings Inc, an estimated $1.13M trimmed.

  • NEA Management Company's largest Q1 2020 buy was Black Diamond Therapeutics: 3,449,845 shares worth $86.1M.
  • NEA Management Company added most to Trillium Therapeutics Inc. in Q1 2020, an estimated $13.7M increase.
  • NEA Management Company's biggest Q1 2020 reduction was Senseonics Holdings Inc, cutting an estimated $1.13M.
  • NEA Management Company fully exited Dermira, Inc. in Q1 2020, selling an estimated $53.2M.
  • NEA Management Company's ten largest holdings make up 66% of its $1.91B portfolio in Q1 2020.
  • NEA Management Company opened 4 new positions and closed 1 in Q1 2020.
  • NEA Management Company's portfolio value fell 9.5% quarter-over-quarter to $1.91B.

Based on NEA Management Company's 13F filing for Q1 2020, filed 6 May 2020.